Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.52 |
| ▸ | PLAT | P00750 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | VCP | P55072 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7430073 | 1.00 | PLG (0.52) | PLGPLATLMNATDP1KMT2A | |
| Trifluoroacetic Acid SCHEMBL7418767 | 0.91 | PLG (0.43) | PLGPLATLMNATDP1KMT2A | |
| Trifluoroacetic Acid SCHEMBL939948 | 0.91 | PLG (0.43) | PLGPLATLMNATDP1KMT2A | |
| SCHEMBL31270861 | 0.88 | — | — | |
| SCHEMBL8596237 | 0.81 | TDP1 (0.76) | PLGPLATLMNATDP1KMT2A | |
| SCHEMBL8596242 | 0.81 | TDP1 (0.76) | PLGPLATLMNATDP1KMT2A | |
| SCHEMBL8595498 | 0.80 | KMT2A (0.46) | PLGPLATLMNATDP1KMT2A | |
| SCHEMBL8595695 | 0.80 | KMT2A (0.46) | PLGPLATLMNATDP1KMT2A | |
| SCHEMBL4040744 | 0.79 | EPHX1 (0.63) | TDP1ALDH1A1CYP3A4EPHX1CYP2D6 | |
| SCHEMBL8601731 | 0.78 | PLG (0.57) | PLGPLATLMNATDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243161-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-12269800-B2 | Delivery of therapeutic alkaloid compounds | SENSORIUM THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250051277-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20240246910-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| US-11999694-B2 | Delivery of therapeutic alkaloid compounds | SENSORIUM THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023076586-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076586-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| WO-2002057248-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002057249-A1 | CYCLIC 2-CARBONYLAMINOKETONES AS INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002057270-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002057246-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| US-6245743-B1 | ADMINISTERING ARGININE-CONTAINING OLIGOPEPTIDE AS ANTICOAGULANT; CARDIOVASCULAR DISORDERS | COR THERAPEUTICS, INC. | 2001-06-12 | — | — | US | disclosed |
| US-6046169-A | Inhibitors of factor XA | COR THERAPEUTICS, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5919765-A | USING A (DI- OR TRI)PEPTIDES | COR THERAPEUTICS, INC. (US) | 1999-07-06 | — | — | US | disclosed |
| EP-0846125-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 1998-06-10 | — | — | EP | disclosed |
| US-5721214-A | PEPTIDE ANTICOAGULANTS | COR THERAPEUTICS, INC. (US) | 1998-02-24 | — | — | US | disclosed |
| WO-1996040743-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051277-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | PLG 917/4885PLAT 1281/4885LMNA 1333/4885 |
| US-20250243161-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | PLG 917/4885PLAT 1281/4885LMNA 1333/4885 |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | PLG 917/4885PLAT 1281/4885LMNA 1333/4885 |
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | PLG 389/4885PLAT 186/4885LMNA 4057/4885 |
| US-20240246910-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | PLG 917/4885PLAT 1281/4885LMNA 1333/4885 |
| US-12269800-B2 | Delivery of therapeutic alkaloid compounds | PNMT, HNMT, NNMT | PLG 917/4885PLAT 1281/4885LMNA 1333/4885 |
| US-11999694-B2 | Delivery of therapeutic alkaloid compounds | PNMT, HNMT, NNMT | PLG 917/4885PLAT 1281/4885LMNA 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.